*  Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors - Full Text...
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Life expectancy of greater than 3 months ...
https://clinicaltrials.gov/ct/show/NCT01017640
*  Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney...
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Life expectancy of greater than 3 months ... Recruitment Status : Withdrawn (Other- Protocol moved to Disapproved) First Posted : October 5, 2015 ...
https://clinicaltrials.gov/ct2/show?term=small+cell+lung+cancer+BMN+673&rank=1
*  Talazoparib, Carboplatin, and Paclitaxel in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by...
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Life expectancy of greater than 12 weeks ... Changes in mutation status [ Time Frame: Baseline to time of progression (up to 4 weeks after last dose of treatment) ]. The ... The frequency of mutation status changes will be analyzed using a paired t-test or nonparametric Wilcoxon Signed Rank test. A ... number and frequency of mutation status changes from the baseline biopsy assessment to the biopsy obtained at the time of ...
https://clinicaltrials.gov/ct2/show/NCT02317874
*  Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by...
Eastern Cooperative Oncology Group (ECOG) performance status =, 1 (Karnofsky ,= 70%). *Life expectancy of greater than 3 months ... mutation status [ Time Frame: Baseline ]. Associations of mutation status with response rate and PFS6months will be assessed ... Associations of mutation status with PFS and overall survival will be assessed using the log rank test. ...
https://clinicaltrials.gov/ct2/show/NCT01643278?recr=Open&cond=%22Sarcoma%22&rank=11
*  Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma - Full...
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Life expectancy of greater than 6 months ...
https://clinicaltrials.gov/show/NCT01330173
*  A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung...
ECOG performance status , 2 (Karnofsky , 60%; see Appendix A).. * Patients must have normal organ and marrow function as ... Patients with brain metastases must have stable neurologic status following local therapy (surgery or radiation) for at least 2 ...
https://clinicaltrials.gov/show/NCT00769600
*  Immunotoxin Therapy and Cytarabine in Treating Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia - Full...
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Life expectancy of greater than 2 months ... History of documented seizure disorder, presence of cerebellar dysfunction, dysphasia or altered mental status on neurological ...
https://clinicaltrials.gov/ct2/show/NCT01408160?cond=%22Acute+lymphoblastic+leukemia%22&rank=6
*  Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa - Full Text View - ClinicalTrials.gov
Performance status: ,50% Lansky; ,50% Karnofsky. * Adequate organ function. *Renal: glomerular filtration rate , 60ml/min/1.73 ...
https://clinicaltrials.gov/show/NCT00478244
*  Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non...
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Leukocytes ,= 3,000/mcL ... if KRAS mutational status cannot be determined on archived tumor tissue from the patient, a needle or excisional biopsy of a ... malignant site may be performed prior to enrollment; mutational status may be determined either by polymerase chain reaction ( ...
https://clinicaltrials.gov/ct2/show/NCT00397384?recr=Open&cond=%22Adenoids%22&rank=11
*  Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer - Full Text View - ClinicalTrials.gov
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Patients with treated brain metastases ...
https://clinicaltrials.gov/show/NCT01251874
*  Perioperative Therapy for Resectable Pancreatic Cancer - Full Text View - ClinicalTrials.gov
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Leucocytes ,= 3,000/uL ... be staged according to American Joint Committee on Cancer 6th Edition incorporating the prefix y to indicate a specimen status- ...
https://clinicaltrials.gov/show/NCT00609336
*  Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural...
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Life expectancy greater than 6 months ... The proportion of patients whose histone acetylation status changes in each group will be estimated with its 95% confidence ... The proportion of patients whose EBV promoter demethylation status changes in each group will be estimated with its 95% ... Performed using a validated high performance liquid chromatography method. Maximum concentration (Cmax) and time to Cmax will ...
https://clinicaltrials.gov/ct2/show/NCT00336063?term=nasopharyngeal+cancer&cond=%22Nasopharyngeal+Carcinoma%22&rank=12
*  Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and...
ECOG performance status ,/= 2 (Karnofsky ,/= 60%).. *Lansky performance status of ,/= 60% for participants 16 years old or ... You will have a dynamic contrast enhanced MRI (DCE-MRI) and diffusion weighted MRI (DW-MRI) scan to check the status of the ... After Cycle 2, you will have a CT or MRI scan after every 2 cycles to check the status of the disease. ...
https://clinicaltrials.gov/ct2/show/record/NCT01552434
*  Cabozantinib-S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer - Full Text View - ClinicalTrials.gov
Eastern Cooperative Oncology Group (ECOG) performance status =, 2 (Karnofsky ,= 60%). *Life expectancy of greater than 3 months ... Baseline molecular status of archival tumor (c-met amplification and mutation status) [ Time Frame: Baseline ]. Will correlate ... Recruitment Status : Suspended (Other - Accrual goal met; amendment in review to add new cohort) First Posted : September 5, ... I. Correlation of clinical response with baseline molecular status of archival tumor (hepatocyte growth factor receptor [c-met ...
https://clinicaltrials.gov/ct2/show/NCT01935934?recr=Open&cond=%22Adenoma%22&rank=4